LivaNova PLC (NASDAQ:LIVN) Short Interest Up 32.7% in January

LivaNova PLC (NASDAQ:LIVN) saw a significant growth in short interest during the month of January. As of January 30th, there was short interest totaling 2,436,767 shares, a growth of 32.7% from the January 15th total of 1,836,041 shares. Currently, 4.5% of the company’s shares are sold short. Based on an average trading volume of 603,535 shares, the days-to-cover ratio is currently 4.0 days. Based on an average trading volume of 603,535 shares, the days-to-cover ratio is currently 4.0 days. Currently, 4.5% of the company’s shares are sold short.

LivaNova Stock Up 1.8%

Shares of LIVN stock traded up $1.16 on Tuesday, hitting $66.96. The stock had a trading volume of 881,922 shares, compared to its average volume of 628,565. The stock’s 50 day moving average is $63.68 and its 200-day moving average is $57.77. The firm has a market capitalization of $3.66 billion, a price-to-earnings ratio of -16.74 and a beta of 0.97. LivaNova has a 52-week low of $32.48 and a 52-week high of $67.92. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.12 and a current ratio of 1.33.

Institutional Trading of LivaNova

Several large investors have recently modified their holdings of the business. Primecap Management Co. CA lifted its stake in shares of LivaNova by 0.7% in the second quarter. Primecap Management Co. CA now owns 4,641,352 shares of the company’s stock worth $208,954,000 after acquiring an additional 32,942 shares in the last quarter. Millennium Management LLC increased its holdings in LivaNova by 22.4% during the 3rd quarter. Millennium Management LLC now owns 2,969,814 shares of the company’s stock worth $155,559,000 after purchasing an additional 544,033 shares during the last quarter. Artisan Partners Limited Partnership raised its position in shares of LivaNova by 94.5% in the 3rd quarter. Artisan Partners Limited Partnership now owns 2,427,045 shares of the company’s stock valued at $127,129,000 after purchasing an additional 1,179,436 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of LivaNova by 83.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock valued at $122,858,000 after buying an additional 1,067,349 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of LivaNova by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 2,332,051 shares of the company’s stock worth $143,491,000 after buying an additional 34,812 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on LIVN shares. The Goldman Sachs Group reissued a “neutral” rating and set a $66.00 target price on shares of LivaNova in a research report on Friday, January 9th. Mizuho boosted their price objective on shares of LivaNova from $70.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Stifel Nicolaus increased their price objective on shares of LivaNova from $65.00 to $70.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. KeyCorp assumed coverage on shares of LivaNova in a report on Friday, December 19th. They set an “overweight” rating and a $81.00 target price on the stock. Finally, Wall Street Zen raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, LivaNova presently has an average rating of “Moderate Buy” and a consensus target price of $69.38.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.